NCT05941507View on ClinicalTrials.gov

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

May 31, 2027

Conditions
Advanced Solid Tumors
Interventions
DRUG

LCB84

TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug

DRUG

Anti-PD-1 monoclonal antibody

anti-PD-1 Ab

Trial Locations (8)

37203

NOT_YET_RECRUITING

Tennessee Oncology, Nashville

48109

RECRUITING

University of Michigan, Ann Arbor

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

75390

NOT_YET_RECRUITING

University of Texas Southwestern Medical Center, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

90048

RECRUITING

Cedars Sinai Medical Center, Los Angeles

02115

RECRUITING

Dana Farber Cancer Institute, Boston

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

Sponsors
All Listed Sponsors
collaborator

AntibodyChem Biosciences, Inc.

UNKNOWN

lead

LigaChem Biosciences, Inc.

INDUSTRY

NCT05941507 - A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter